March 7th 2025Article
The use of ivonescimab was correlated with a median 5.3-month improvement in progression-free survival (PFS) over pembrolizumab in patients with PD-L1 positive non-small cell lung cancer, according to CT and MRI findings from a phase 3 randomized multicenter trial.